Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer

Head and Neck

Volumn 33, Issue 12, 2011, Pages 1666-1674

  Wolf, Gregory T ^a   Fee Jr , Willard E ^b   Dolan, Robert W ^c   Moyer, Jeffrey S ^a   Kaplan, Michael J ^b   Spring, Paul M ^d   Suen, James ^d   Kenady, Daniel E ^e   Newman, Jason G ^f   Carroll, William R ^g   Gillespie, M Boyd ^h   Freeman, Scott M ⁱ   Baltzer, Lorraine ^j   Kirkley, Terry D ^j   Brandwein, Harvey J ⁱ   Hadden, John W ⁱ  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF ALABAMA HOSPITAL   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ IRX Therapeutics   (United States)

^j NONE   (United States)

more..

Author keywords

cytokine; head and neck squamous cell carcinoma; immune response; IRX 2; phase 2

Indexed keywords

CYCLOPHOSPHAMIDE; GLUCONATE ZINC; IMMUNOMODULATING AGENT; INDOMETACIN; IRX 2; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CELLULAR IMMUNITY; CONSTIPATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; INJECTION SITE PAIN; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; SURGICAL INFECTION; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CYCLOPHOSPHAMIDE; CYTOKINES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCONATES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; INDOMETHACIN; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; INTERLEUKIN-1BETA; INTERLEUKIN-2; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 81255187885     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21660     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
3. Wu AA, Niparko KJ, Pai SI,. Immunotherapy for head and neck cancer. J Biomed Sci 2008; 15: 275-289.
4. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review. SEER web site 2008. Accessed May 30, 2008.
5. Alhamarneh O, Amarnath SM, Stafford ND, Greenman J,. Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer? Head Neck 2008; 30: 251-261. (Pubitemid 351251710)
6. Whiteside TL,. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005; 24: 95-105. (Pubitemid 40576066)
7. Leibowitz MS, Nayak JV, Ferris RL,. Head and neck cancer immunotherapy: clinical evaluation. Curr Oncol Rep 2008; 10: 162-169. (Pubitemid 351395477)
8. Patt BS, Close LG, Vuitch F,. Prognostic significance of sinus histiocytosis in metastatic laryngeal cancer. Laryngoscope 1993; 103: 498-502. (Pubitemid 23136172)
9. Argiris A, Karamouzis MV, Raben D, Ferris RL,. Head and neck cancer. Lancet 2008; 371: 1695-1709. (Pubitemid 351671886)
10. Molling JW, Langius JA, Langendijk JA, et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 2007; 25: 862-868. (Pubitemid 350002887)
11. 1 potently augments T-lymphocyte responses of hydrocortisone-treated aged mice. Int J Immunopharmacol 1995; 17: 821-828.
12. Egan JE, Quadrini KJ, Santiago-Schwarz F, Hadden JW, Brandwein HJ, Signorelli KL,. IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro. J Immunother 2007; 30: 624-633. (Pubitemid 47229697)
13. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H,. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862-2868. (Pubitemid 40446280)
14. Lönnroth C, Andersson M, Arvidsson A, et al. Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 2008; 8: 5.
15. Lieb J,. Antidepressants, prostaglandins and the prevention and treatment of cancer. Med Hypotheses 2007; 69: 684-689. (Pubitemid 47043269)
16. Fraker PJ, King LE,. Reprogramming of the immune system during zinc deficiency. Annu Rev Nutr 2004; 24: 277-298. (Pubitemid 38938793)
17. Prasad AS, Beck FW, Doerr TD, et al. Nutritional and zinc status of head and neck cancer patients: an interpretive review. J Am Coll Nutr 1998; 17: 409-418. (Pubitemid 28445329)
18. Freeman SM, Barrera JL, Kenady DE, et al. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol 2010. [Epub ahead of print]
19. Hamada I, Kato M, Okada K,. Multi-cytokine therapy for advanced renal cell carcinoma: determination of the minimal effective dose. Anticancer Res 2002; 22: 2429-2436. (Pubitemid 34857078)
20. Abdel-Wahab M, El-Shennawy F, Agha S, et al. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2). Hepatogastroenterology 1999; 46 Suppl 1: 1293-1296. (Pubitemid 29241647)
21. Vlock DR, Snyderman CH, Johnson JT, et al. Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. J Immunother Emphasis Tumor Immunol 1994; 15: 134-139. (Pubitemid 24047546)
22. Pulley MS, Nagendran V, Edwards JM, Dumonde DC,. Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer. Lymphokine Res 1986; 5 Suppl 1: S157-S163. (Pubitemid 17207892)
23. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213. (Pubitemid 36077915)
24. Haanen JB, Baars A, Gomez R, et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 2006; 55: 451-458. (Pubitemid 43076897)
25. Wolf GT, Schmaltz S, Hudson J, et al. Alterations in T-lymphocyte subpopulations in patients with head and neck cancer. Correlations with prognosis. Arch Otolaryngol Head Neck Surg 1987; 113: 1200-1206. (Pubitemid 18035876)
26. Czystowska M, Han J, Szczepanski MJ, et al. IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ 2009; 16: 708-718.
27. Rapidis AD, Wolf GT,. Immunotherapy of head and neck cancer: current and future considerations. J Oncol 2009; 2009: 346345.